Skip to main content
. 2021 Aug 13;6(2):1–26. doi: 10.20411/pai.v6i2.461

Figure 2.

Figure 2.

Effect of atorvastatin treatment on monocyte cell surface markers: Shown are the predefined primary outcomes (A) and secondary outcomes (B), along with exploratory outcomes that reached a nominal P≤0.05 threshold (C). Data represent the mean biomarker levels by study arm with 95% confidence intervals, with atorvastatin shown in red and placebo in green. Raw P value of the difference between the 2 groups over 12 weeks is shown.